1INTRODUCTIONIn New Zealand, the presence of the biomarker human epidermal growth factor receptor 2 (HER2) in women with breast cancer has been commonly ascertained since 1998, and routinely since 2006. It has been found to be present in approximately 15–20% of breast cancers, presenting more commonly in breast cancers of younger women. It is known that women who have HER2 positive (+ve) breast cancer have a poorer prognosis compared to women with HER2 negative (–ve) disease.Trastuzumab (Herceptin) is a targeted therapy for patients with HER2+ve breast cancer. Randomized clinical trials have shown that trastuzumab reduced breast cancer recurrence and mortality in women with early‐stage HER2+ve breast cancer after surgery. A study combining data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐31 and North Central Cancer Treatment Group (NCCTG) N9831 clinical trials with a median follow‐up time of 8 years demonstrated a hazard ratio of 0.63 (95% CI: 0.54–0.73) in breast cancer‐specific mortality and a hazard ratio of 0.60 (95% CI: 0.53–0.68) in all‐cause mortality after adding 12 months trastuzumab to chemotherapy for HER2+ve stage I–III breast cancer.Trastuzumab was first licensed by the US FDA (Federal Drug Regulatory Authority) in 1998 for metastatic HER2+ve breast cancer and
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera